Related Experiment Videos
Adjuvant fosfomycin medication in chronic osteomyelitis
A Meissner1, R Haag, R Rahmanzadeh
1Abteilung für Unfall- und Wiederherstellungschirurgie, Klinikum Steglitz der FU Berlin.
Infection
|May 1, 1989
Summary
Adjuvant fosfomycin therapy shows promising results for chronic post-traumatic osteomyelitis, with over 60% of patients achieving very good or good outcomes. Bone concentrations of fosfomycin were found to be effective against common pathogens like Staphylococcus aureus.
Area of Science:
- Orthopedics
- Infectious Diseases
- Pharmacology
Background:
- Chronic post-traumatic osteomyelitis presents a significant therapeutic challenge.
- Adjuvant antibiotic therapy is crucial for managing persistent bone infections.
Purpose of the Study:
- To evaluate the therapeutic effectiveness of adjuvant fosfomycin in chronic post-traumatic osteomyelitis.
- To determine fosfomycin bone concentrations and their correlation with treatment outcomes.
Main Methods:
- Prospective clinical trial involving 60 patients with chronic osteomyelitis.
- Isolation and sensitivity testing of pathogens, predominantly Staphylococcus aureus.
- Measurement of fosfomycin concentrations in bone interstitial fluid.
- Assessment of treatment outcomes over a mean follow-up of 37 months.
Main Results:
- Pathogens were sensitive to fosfomycin, with MIC90 values ranging from 2 to 64 mg/l.
- Fosfomycin bone concentrations varied significantly, particularly with higher initial doses (10g).
- Over 58% of patients achieved 'very good' or 'good' treatment outcomes, while 26.4% had unsatisfactory results.
Conclusions:
- Adjuvant fosfomycin therapy is a viable option for chronic post-traumatic osteomyelitis.
- Achieved bone concentrations suggest effective antimicrobial activity in the infected site.
- Further research may optimize dosing strategies to improve outcomes and reduce treatment failures.